sb 203580 has been researched along with fsl-1 lipoprotein, synthetic in 1 studies
Studies (sb 203580) | Trials (sb 203580) | Recent Studies (post-2010) (sb 203580) | Studies (fsl-1 lipoprotein, synthetic) | Trials (fsl-1 lipoprotein, synthetic) | Recent Studies (post-2010) (fsl-1 lipoprotein, synthetic) |
---|---|---|---|---|---|
3,489 | 4 | 1,137 | 66 | 0 | 40 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Hasebe, A; Into, T; Nakamura, J; Ohata, N; Shibata, K; Watanabe, T | 1 |
1 other study(ies) available for sb 203580 and fsl-1 lipoprotein, synthetic
Article | Year |
---|---|
Signaling pathways induced by lipoproteins derived from Mycoplasma salivarium and a synthetic lipopeptide (FSL-1) in normal human gingival fibroblasts.
Topics: Bacterial Proteins; Blotting, Western; Diglycerides; Enzyme Inhibitors; Fibroblasts; Flavonoids; Gingiva; Humans; Imidazoles; Interleukin-6; Lipoproteins; Mycoplasma; NF-kappa B; Oligopeptides; Phosphorylation; Pyridines; Signal Transduction; Transcription Factor AP-1 | 2002 |